Zeytinci, EsraUguz, FarukSahingoz, MineSari, SerapKayhan, Fatih2020-03-262020-03-2620091017-7833https://hdl.handle.net/20.500.12395/23253Add-on therapy with pramipexole in treatment resistant dysthymic disorder: A case report Despite a wide range of alternative antidepressant drugs, a considerable rate of patients with dysthymic disorder do not response to these treatments. Usually combined pharmacological drugs and augmentation therapies are used to manage this chronic psychiatric disorder. Pramipexole, a new dopamine agonist, is approved for Parkinson's disease and restless leg syndrome but accumulating evidence suggests the usage of the drug as an antidepressant. We present a young man with a history of dysthymic disorder for 15 years who improved after adding low dose pramipexole to the prior treatment.trinfo:eu-repo/semantics/closedAccessDysthymiapramipexoleaugmentation therapiesArticle19S198S199WOS:000209020900063N/A